Twist Bioscience Corporation (TWST)
| Market Cap | 5.76B +204.7% |
| Revenue (ttm) | 409.48M +17.8% |
| Net Income | -81.28M |
| EPS | -1.34 |
| Shares Out | 62.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,064,803 |
| Open | 86.16 |
| Previous Close | 85.00 |
| Day's Range | 85.50 - 93.80 |
| 52-Week Range | 23.30 - 93.80 |
| Beta | 2.21 |
| Analysts | Strong Buy |
| Price Target | 74.10 (-19.94%) |
| Earnings Date | Aug 3, 2026 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for TWST stock is "Strong Buy." The 12-month stock price target is $74.1, which is a decrease of -19.94% from the latest price.
News
Twist Bioscience price target raised to $95 from $65 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience (TWST) to $95 from $65 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Twist Bioscience files automatic mixed securities shelf
16:10 EDT Twist Bioscience (TWST) files automatic mixed securities shelf
Ozempic Linked To Lower Risk Of Violence In New Study
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J...
Twist Bioscience price target raised to $89 from $68 at TD Cowen
TD Cowen raised the firm’s price target on Twist Bioscience (TWST) to $89 from $68 and keeps a Buy rating on the shares. The firm noted shares have been strong…
Canaccord starts Twist Bioscience at Buy on ‘differentiated’ chip
Canaccord initiated coverage of Twist Bioscience (TWST) with a Buy rating and $90 price target The firm says Twist’s silicon-based miniaturized “lab-on-a-chip” method provides “significantly higher” t...
Twist Bioscience initiated with a Buy at Canaccord
Canaccord initiated coverage of Twist Bioscience (TWST) with a Buy rating and $90 price target
Twist Bioscience initiated with an Overweight at Piper Sandler
Piper Sandler analyst David Westenberg initiated coverage of Twist Bioscience (TWST) with an Overweight rating and $85 price target The firm launched coverage of the life science tools sector with…
Twist Bioscience Transcript: 46th Annual William Blair Growth Stock Conference
The company leverages silicon-based DNA synthesis to deliver rapid innovation, automation, and cost reductions, driving strong revenue growth and expanding its addressable market. With a diversified product portfolio and customer base, it targets adjusted EBITDA breakeven by Q4 and plans further expansion into mRNA and gene therapies.
Twist Bioscience Slides: Corporate presentation
Twist Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience Transcript: Investor Day 2026
Industry-leading DNA synthesis and automation have enabled rapid expansion into AI-driven drug discovery, antibody engineering, and sustainability applications. Customer collaborations have driven major improvements in success rates, scale, and data generation, fueling strong revenue growth and positioning the platform for leadership in both healthcare and industrial biotechnology.
Twist Bioscience Slides: FY 2026
Twist Bioscience has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 21, 2026.
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience...
Twist Bioscience announces inducement grants under Nasdaq listing rule
Twist Bioscience (TWST) announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units and up to 13,348 performance stock units, will be granted to 53 recently…
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Twist Bioscience price target raised to $60 from $55 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Twist Bioscience (TWST) to $60 from $55 and keeps a Buy rating on the shares. The firm adjusted estimates following…
Twist Bioscience price target raised to $65 from $50 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Twist Bioscience (TWST) to $65 from $50 and keeps an Outperform rating on the shares. The firm updated its…
Twist Bioscience upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Twist Bioscience (TWST) to Outperform from Market Perform with a $70 price target
Twist Bioscience price target raised to $65 from $55 at Barclays
Barclays raised the firm’s price target on Twist Bioscience (TWST) to $65 from $55 and keeps an Overweight rating on the shares. The company reported solid results “across the board,”…
Twist Bioscience Earnings Call Transcript: Q2 2026
Q2 revenue grew 19% YoY to $110.7M, with gross margin expanding to 51.6% and strong growth in DNA synthesis, protein solutions, and NGS. Fiscal 2026 guidance was raised, with adjusted EBITDA breakeven expected in Q4, driven by robust demand in AI-enabled drug discovery and diagnostics.
Twist Bioscience Earnings release: Q2 2026
Twist Bioscience released its Q2 2026 earnings on May 4, 2026, summarizing the period's financial results.
Twist Bioscience Slides: Q2 2026
Twist Bioscience has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 4, 2026.
Twist Bioscience Quarterly report: Q2 2026
Twist Bioscience has published its Q2 2026 quarterly earnings report on May 4, 2026.
Twist Bioscience sees Q3 revenue $114M-$115M, consensus $111.27M
The company said, ” As previously discussed, we expect NGS to be the driver of sequential growth in H2 and return to 20% growth by 4Q.”
Twist Bioscience expects to achieve adjusted EBITDA breakeven for Q4
07:22 EDT Twist Bioscience (TWST) expects to achieve adjusted EBITDA breakeven for Q4